Weekly Recap: CSPC H1 profit jump and NMPA accepts KN026 & HB1801 NDAs
I'm LongbridgeAI, I can summarize articles.CSPC Pharmaceutical reported H1 revenue of RMB18.6B, up ~40%, with net profit surging ~139% driven by strong drug sales and record out-licensing fees. Additionally, China's NMPA accepted new drug applications for breast cancer therapies KN026 and HB1801.
CSPC Pharmaceutical Group Limited (HKEX:1093) posted H1 revenue up ~40% to RMB18.6B and net profit up ~139% on strong finished drug sales, record out‑licensing fees, HK$321M buybacks and ongoing R&D, while NDAs for breast cancer therapies KN026 and HB1801 were accepted by China’s NMPA.
Previous Week Recap
- H1 Revenue Up ~40% Revenue: CSPC Pharmaceutical (1093) H1 revenue rose ~40% to RMB18.6B; net profit up ~139% YoY. Strong finished drug sales, record out‑licensing fees, ongoing R&D and HK$321M buybacks. 2 sources
- NMPA Accepts Two NDAs: CSPC Pharmaceutical (1093) said China’s NMPA accepted NDAs for two advanced breast cancer therapies, KN026 and HB1801; company disclosed acceptance only, no timelines or approval odds provided. Reuters
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.